Veterinary Autoimmune Disease Therapeutics Market - By Therapy (Corticosteroids, Azathioprine), Disease (Hypothyroidism, Pemphigus Disease), Animal Type (Companion, Livestock), Distribution Channel (Hospitals, Clinics), Global Forecast (2023 - 2032)

Veterinary Autoimmune Disease Therapeutics Market - By Therapy (Corticosteroids, Azathioprine), Disease (Hypothyroidism, Pemphigus Disease), Animal Type (Companion, Livestock), Distribution Channel (Hospitals, Clinics), Global Forecast (2023 - 2032)

Global Veterinary Autoimmune Disease Therapeutics Market will witness over 5.3% CAGR between 2023 and 2032. The rising incidence of autoimmune diseases in animals, including dogs and cats, propels the demand for effective treatments. Increasing pet ownership and the deepening bond between humans and their pets contribute to a willingness to invest in advanced treatments.

For instance, according to a Forbes report from June 2023, pet ownership in the United States reached 66%, encompassing 86.9 million households—an increase from 56% recorded in 1988. These statistics prove the enduring significance of pets in people's lives. For many, pets provide companionship and emotional support, with 85% of dog owners and 76% of cat owners considering their furry friends as integral family members. Advancements in veterinary medicine and diagnostics are expanding treatment options. Additionally, the growing awareness of autoimmune conditions in animals fosters veterinary autoimmune disease therapeutics market growth.

The overall Veterinary Autoimmune Disease Therapeutics Market is classified based on therapy, disease, and region.

The azathioprine segment will undergo significant development from 2023 to 2032. Azathioprine is a crucial immunosuppressive drug used to manage autoimmune disorders in animals. Its efficacy in controlling excessive immune responses and alleviating symptoms like inflammation and organ damage makes it a sought-after treatment option in veterinary autoimmune disease therapeutics, contributing significantly to veterinary autoimmune disease therapeutics market demand.

The pemphigus disease segment will register a commendable CAGR from 2023 to 2032. Pemphigus is an autoimmune condition that affects pets, leading to painful skin and mucous membrane lesions. Veterinary autoimmune disease therapeutics, including medications like corticosteroids and immunosuppressants, are in demand to manage and alleviate the symptoms of pemphigus, improving the quality of life for affected animals and driving veterinary autoimmune disease therapeutics market revenue.

Europe veterinary autoimmune disease therapeutics market will showcase an appreciable CAGR from 2023 to 2032. The region's deep-rooted affection for pets, stringent animal welfare standards, and advanced veterinary care infrastructure drive the need for autoimmune disease therapeutics. Increasing efforts from countries to curb the mistreatment of animals support market growth in the region. For instance, according to news from June 2022, French lawmakers passed an amendment to the Act on the Treatment of Animals in November 2021. According to this amendment, pet stores will be prohibited from exhibiting and selling dogs and cats starting in 2024.

In addition, the public will no longer be permitted to conduct online transactions involving dogs and cats. The regulation intends to combat the escalating issue of pet abandonment, which witnessed an increase during the COVID-19 pandemic. With increasing awareness of pet health and autoimmune conditions, Europe remains a significant market for veterinary autoimmune disease treatments, supporting the well-being of beloved companion animals across the continent.